With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.131274-22-1,Tri-tert-butylphosphonium tetrafluoroborate,as a common compound, the synthetic route is as follows.
Step A (2E)-3-(2-Phenyl-5-pyrimidinyl)-2-propenoic Acid Methyl Ester Dioxane (1.3 mL) was added to a mixture of 5-bromo-2-phenylpyrimidine (310 mg, 1.32 mmol, prepared as described in Org. Lett. 2002, 4, 513), tri-t-butylphosphonium tetrafluoroborate (11 mg, 0.038 mmol), and tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.020 mmol). N-Methyldicyclohexylamine (0.31 mL, 1.45 mmol) and methyl acrylate (0.24 mL, 2.67 mmol) were added and the mixture was stirred for 72 h at room temperature. The mixture was diluted with ethyl acetate, filtered through a small plug of silica gel which was washed with additional ethyl acetate, and the combined filtrates were concentrated. The residue was triturated with 5:1 hexane/ethyl acetate and the solid was filtered and dried in vacuo to provide 178 mg (56%) of the title compound as an off-white solid. MS 241 (M+H)+.
131274-22-1 Tri-tert-butylphosphonium tetrafluoroborate 2734635, achiral-phosphine-ligands compound, is more and more widely used in various.
Reference£º
Patent; Henninger, Todd C.; Macielag, Mark J.; Tennakoon, Manomi A.; Xu, Xiaodong; US2003/220272; (2003); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate